Vital Therapies Announces Launch of Proposed Follow-On Offering

SAN DIEGO, Sept. 30, 2014 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute liver failure, today announced that it plans to commence an underwritten public offering of 2,500,000 shares of its common stock. In addition, Vital Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 375,000 shares of its common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

BofA Merrill Lynch is acting as sole book-running manager for the offering. William Blair is acting as lead manager and Canaccord Genuity and SunTrust Robinson Humphrey are acting as co-managers for the offering.

The proposed offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the offering may be obtained from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, Email: [email protected].

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Vital Therapies, Inc.

Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute liver failure. The Company's lead product-candidate, the ELAD System, is an extracorporeal bio-artificial liver currently in Phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.

CONTACT: Al Kildani
         Vice President, Investor Relations and Business Development
         Vital Therapies, Inc.
         858-673-6840
         [email protected]

You May Also Be Interested In

• Tenax shares Phase 3 LEVEL trial data at ESC Congress 2026
• AiRWA receives Nasdaq deficiency notice over late 10-K filing
• FDA approves Takeda's rusfertide for polycythemia vera treatment